You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
SMALL BUSINESS INNOVATION RESEARCH (SBIR): UNIVERSAL MEDIA FOR MAINTENANCE OF MESODERMAL LINEAGE MPS SYSTEMS
SBC: LaCell LLC Topic: NIDAMicrophysiological systemsMPSdevelopment has advanced as a means to reducerefineand replace animal studiesto improve models of human diseaseUsage of MPS systems for such applications will require standardization of technology componentsTowards this effortNational Center for Advancing Translational SciencesNCATSinvestigators have identified the need for a universal medium for supporting the surviva ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive biomarkers for gastrointestinal disease in preterm infants
SBC: CHOSEN DIAGNOSTICS INC Topic: NICHDThe goal and significance of this project is to develop a clinically usable diagnostic test for gastrointestinal disease and to reduce healthcare costsNecrotizing enterocolitisNECis the most frequent and lethal gastrointestinal disease for preterm infantsIt affects newborns at a rate ofperUS births per year and has an average total in hospital treatment cost of $per patientAlthough first described ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimer’s Disease
SBC: Oleolive, Inc. Topic: NIAPROJECT SUMMARY Alzheimer’s disease (AD) is the sixth leading cause of death in United States, yet this indication lacks truly effective therapeutics to mitigate this disease. To address this problem, a novel (partial) peroxisomal proliferator activating–gamma (PPAR) nuclear receptor agonist (AU-9) that has selective amino acid interactions in the receptor ligand-binding domain was develope ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Nanoentrapped polyphenol coatings for sustained release from angioplasty balloons
SBC: REQUISITE BIOMEDICAL, LLC Topic: NHLBIPROJECT SUMMARYPeripheral artery diseasePADis a serious cardiovascular disease affectingmillion people worldwidePAD is defined by a blockage of arteries in the lower extremitiesand is associated with painpoor wound healingand without interventionlimb loss and deathDrug coated balloonsDCBare an emerging clinical intervention aimed at clearing blocked arteriesparticularly those that are difficult to ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Repurposing a Pinworm Drug to Treat Pulmonary Fibrosis
SBC: SegueTX-Pancreatic Cancer, L.L.C. Topic: NHLBIPROJECT SUMMARY Pulmonary fibrosis is a leading cause of death worldwide. With a median survival of only 2.5 years after diagnosis, it is responsible for millions of deaths worldwide and billions in health care costs each year. Besides mortality, pulmonary fibrosis, of which the idiopathic type is most common, brings about tragic morbidity. Without a known cause of idiopathic pulmonary fibrosis, v ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr
SBC: DEKK-TEC INC Topic: N/ADESCRIPTION (provided by applicant): The object of the proposed research is to conduct a Phase 1 clinical trial with 4-demethyl-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN), a carbonate derivative of 4-demethyl-penclomedine (DM-PEN) in patients with ad vanced cancer. The latter is the antitumor active, non-neurotoxic metabolite of penclomedine (PEN). PEN was active in clinical trials but posse ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
High efficiency Hyper/Hypothermia
SBC: LIFE RECOVERY SYSTEM, INC. Topic: N/ADESCRIPTION (provided by applicant): Sudden cardiac arrest remains a serious public health issue. Approximately 350,000 individuals are stricken in the U.S. annually, with overall survival rates on the order of only 5%. Even with the immediate availabi
SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Brachytherapy Delivery System for Treatment of Lung Cancer
SBC: Source Production & Equipment Co., Inc. Topic: N/ADESCRIPTION (provided by applicant): This Phase II program intends to continue to develop an improved brachytherapy delivery system for treatment of lung cancer by incorporating radioactive 169Ytterbium sources into surgical staples used in lung resect ion. For patients with compromised cardiopulmonary status, the inclusion of brachytherapy with sublobular resection has shown a significant imp ...
SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Intensity Modulated Breast Brachytherapy System
SBC: Source Production & Equipment Co., Inc. Topic: N/ADESCRIPTION (provided by applicant): The overall objective of this Phase I program is to demonstrate the feasibility of delivering intensity modulated breast brachytherapy, permitting balloon-based breast brachytherapy to better conform to patient anatomy, reduce potential toxicity by reducing skin dose, and permit this technique to be applied to a greater number of patients who would now be excl ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
HDR Brachytherapy for Intraocular Melanoma
SBC: Source Production & Equipment Co., Inc. Topic: N/ADESCRIPTION (provided by applicant): HDR Brachytherapy for Intraocular Melanoma - Project Summary/Abstract The overall objective of this Phase I program is to develop a brachytherapy system for the treatment of intraocular melanoma that reduces hospitaliza tion time, provides improved dosimetry to reduce complications, improves safety for the clinician and reduces cost. This will be achieved throu ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health